FDA COVID-19 Update for July 9, 2020

July 9, 2020

FDA today continued to take action in the ongoing response to the COVID-19 pandemic:

  • Today, a U.S. District Court in Florida granted a motion for default judgment and a permanent injunction against the Genesis II Church of Health and Healing, Jonathan Grenon, and Jordan Grenon for violating federal law by distributing their product, “Miracle Mineral Solution,” an industrial bleach that the defendants claim is a cure for COVID-19 and other serious diseases. The order issued today permanently prohibits the defendants from selling or distributing unapproved or misbranded products, such as Mineral Miracle Solution (MMS). In prior warning statements, the FDA has urged consumers not to purchase or use MMS, explaining that drinking MMS is the same as drinking bleach and can cause dangerous side effects, including severe vomiting, diarrhea, and life-threatening low-blood pressure. In May, the federal judge entered a preliminary injunction against the Genesis II Church of Health and Healing and four individual defendants associated with the entity.
  • Testing updates:
    • To date, the FDA has currently authorized 171 tests under EUAs; these include 142 molecular tests, 27 antibody tests, and 2 antigen tests.
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.
Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic. Phase 1A clinical trial to initiate patient enrolment in 2024. Phase 1A clinical trial will enroll patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

By using this website you agree to accept Medical Device News Magazine Privacy Policy